Upon activation through Toll-like receptors (TLRs), DCs upregulate MHC and co-stimulatory molecules, including CD40 and CD80/CD86, all of which interact with T cells to promote a proinflammatory or anti-tumor response. Here, CD86 is linked to neoplasm.